Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Ogyu K, Noda Y, Yoshida K, Kurose S, Masuda F, Mimura Y, Nishida H, Plitman E, Tarumi R, Tsugawa S, Wada M, Miyazaki T, Uchida H, Graff-Guerrero A, Mimura M, Nakajima S.
Ogyu K, et al. Among authors: mimura m, mimura y.
Neuropsychopharmacol Rep. 2020 Jun;40(2):138-149. doi: 10.1002/npr2.12103. Epub 2020 Mar 16.
Neuropsychopharmacol Rep. 2020.
PMID: 32180369
Free PMC article.
Clinical Trial.